← Leaderboards
Richard W Price
University Of California San Francisco
$15,279,456
Attributed
$15,279,456
Total exposure
19
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$15,279,456 · 19
By mechanism
R01$11,088,786 · 6
P01$2,200,792 · 2
T32$813,538 · 1
R21$776,033 · 2
M01$400,307 · 8
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Bruce T. Shiramizu$5,736,732
- Michael Shannon McGrath$55,606,332
- Warner C Greene$31,742,202
- Brinda Emu$2,441,085
- Stewart A Anderson$16,418,580
Others in their field
Top investigators on “Cerebrospinal Fluid”
- Randall J Bateman · Washington University$126,806,580
- Michael W Weiner · Northern California Institute Res &Educ$109,344,346
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$77,708,113
- Sid E O'Bryant · University Of North Texas Hlth Sci Ctr$69,879,924
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Paul S. Aisen · Cognition Therapeutics, Inc.$51,064,965
Research focus
Cerebrospinal FluidHiv InfectionsHuman SubjectClinical ResearchAids TherapyHuman Therapy EvaluationAids Dementia ComplexNeuraxisHuman Immunodeficiency Virus 1BloodAntiviral AgentsInfectionViralNeurologicImmuneAntiaids AgentNeuropsychological TestsAids /Hiv NeuropathyPlasmaT-LymphocyteAntiretroviral TherapyBrainChronicCd4 Positive T Lymphocytes
Grant awards (76)
Compartmentalized CSF viral escape and the CNS HIV reservoir$360,447
R01 · FY2020 · NS · contact PI
Compartmentalized CSF viral escape and the CNS HIV reservoir$692,831
R01 · FY2019 · NS · contact PI
Compartmentalized CSF viral escape and the CNS HIV reservoir$692,831
R01 · FY2018 · NS · contact PI
Compartmentalized CSF viral escape and the CNS HIV reservoir$692,820
R01 · FY2017 · NS · contact PI
Compartmentalized CSF viral escape and the CNS HIV reservoir$694,735
R01 · FY2016 · NS · contact PI
Compartmentalized CSF viral escape and the CNS HIV reservoir$763,785
R01 · FY2015 · NS · contact PI
Dynamics of CNS Treatment Effects$299,137
P01 · FY2015 · MH · contact PI
Dynamics of CNS Treatment Effects$356,666
P01 · FY2014 · MH · contact PI
Central Nervous System HIV Translational Research Training Program$158,892
T32 · FY2014 · MH · contact PI
Dynamics of CNS Treatment Effects$344,094
P01 · FY2013 · MH · contact PI
Central Nervous System HIV Translational Research Training Program$184,960
T32 · FY2013 · MH · contact PI
Defining CNS HIV Infection in Treated Patients: Foundation for Eradication$163,897
R21 · FY2013 · MH · contact PI
Dynamics of CNS Treatment Effects$357,049
P01 · FY2012 · MH · contact PI
Defining CNS HIV Infection in Treated Patients: Foundation for Eradication$226,042
R21 · FY2012 · MH · contact PI
Central Nervous System HIV Translational Research Training Program$205,683
T32 · FY2012 · MH · contact PI
Dynamics of CNS Treatment Effects$374,719
P01 · FY2011 · MH · contact PI
Central Nervous System HIV Translational Research Training Program$131,995
T32 · FY2011 · MH · contact PI
CSF & Lymphocyte Dynamics in HIV Infection$352,972
R01 · FY2010 · MH · contact PI
The Cerebrospinal Fluid Proteome in HIV-1 Infection and Opiate Addiction$212,429
P01 · FY2010 · DA · contact PI
The Neuropathobiology of Primary HIV-1 Infection$164,267
R01 · FY2010 · MH · contact PI
Central Nervous System HIV Translational Research Training Program$132,008
T32 · FY2010 · MH · contact PI
CSF & Lymphocyte Dynamics in HIV Infection$352,774
R01 · FY2009 · MH · contact PI
Pilot Study of Treatment Augmentation on CNS Immunoactivation in Treated HIV-1 In$193,125
R21 · FY2009 · MH · contact PI
The Cerebrospinal Fluid Proteome in HIV-1 Infection and Opeate Addiction$170,967
P01 · FY2009 · DA · contact PI
CSF & Lymphocyte Dynamics in HIV Infection$352,586
R01 · FY2008 · MH · contact PI
Pilot Study of Treatment Augmentation on CNS Immunoactivation in Treated HIV-1 In$192,969
R21 · FY2008 · MH · contact PI
The Cerebrospinal Fluid Proteome in HIV-1 Infection and Opeate Addiction$85,731
P01 · FY2008 · DA · contact PI
CSF & Lymphocyte Dynamics in HIV Infection$357,888
R01 · FY2007 · MH · contact PI
CSF & Lymphocyte Dynamics in HIV Infection$381,183
R01 · FY2006 · MH · contact PI
CSF Molecular Marker Study Consortium$259,629
R01 · FY2006 · NS · contact PI
CSF Molecular Marker Study Consortium$264,898
R01 · FY2005 · NS
NEUROLOGICAL CONSEQUENCES OF TREATMENT FAILURE IN HIV$167,529
M01 · FY2005 · RR
CSF ANALYSIS OF HIV-1 VIRAL BURDEN IN HIV-1$23,499
M01 · FY2005 · RR
CSF HIV &LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY$344,525
R01 · FY2004 · MH
Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect$313,650
R01 · FY2004 · NS
CSF Molecular Marker Study Consortium$264,751
R01 · FY2004 · NS
Neurological consequences of treatment failure in HIV$171,838
M01 · FY2004 · RR
CSF analysis of HIV-1 viral burden in HIV-1$19,639
M01 · FY2004 · RR
California NeuroAIDS tissue network$15,546
M01 · FY2004 · RR
CSF HIV &LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY$344,525
R01 · FY2003 · MH
Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect$313,650
R01 · FY2003 · NS
CSF Molecular Marker Study Consortium$265,601
R01 · FY2003 · NS
CSF HIV &LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY$344,525
R01 · FY2002 · MH
Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect$313,650
R01 · FY2002 · NS
CSF Molecular Marker Study Consortium$300,807
R01 · FY2002 · NS
ACTG 363: EFFECTS OF CIDOFOVIR FOR TREATING PROGRESSIVE MULTIFOCAL PML IN AIDS$0
M01 · FY2002 · RR
CEREBROSPINAL FLUID ANALYSIS OF HIV 1 VIRAL BURDEN IN HIV INFECTED SUBJECTS$0
M01 · FY2002 · RR
CEREBROSPINAL FLUID ANALYSIS OF HIV 1 VIRAL BURDEN IN HIV INFECTED SUBJECTS$0
M01 · FY2002 · RR
ACTG 363: EFFECTS OF CIDOFOVIR FOR TREATING PROGRESSIVE MULTIFOCAL PML IN AIDS$0
M01 · FY2002 · RR
CSF IN SEVERE AIDS DEMENTIA COMPLEX TREATED WITH A NEW ANTIRETROVIRAL$0
M01 · FY2002 · RR
CSF IN SEVERE AIDS DEMENTIA COMPLEX TREATED WITH A NEW ANTIRETROVIRAL$0
M01 · FY2002 · RR
ACTG301--TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX W/ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
ACTG301--TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX W/ANTIRETROVIRAL THERAPY$0
M01 · FY2002 · RR
CSF HIV &LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY$344,525
R01 · FY2001 · MH
Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect$325,525
R01 · FY2001 · NS
NEUROLOGICAL EVALUATION OF THE AIDS DEMENTIA COMPLEX IN ACTG CLINICAL TRIALS$140,288
R01 · FY2001 · NS
Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect$50,000
R01 · FY2001 · NS
ACTG301--TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX W/ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
ACTG 363: EFFECTS OF CIDOFOVIR FOR TREATING PROGRESSIVE MULTIFOCAL PML IN AIDS$0
M01 · FY2001 · RR
CEREBROSPINAL FLUID ANALYSIS OF HIV 1 VIRAL BURDEN IN HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
CSF IN SEVERE AIDS DEMENTIA COMPLEX TREATED WITH A NEW ANTIRETROVIRAL$0
M01 · FY2001 · RR
CFS FLUID AFTER RETROVIRAL TREATMENT FOR HIV$409,127
R01 · FY2000 · NS
CSF HIV &LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY$356,400
R01 · FY2000 · MH
NEUROLOGICAL EVALUATION OF THE AIDS DEMENTIA COMPLEX IN ACTG CLINICAL TRIALS$273,591
R01 · FY2000 · NS
ACTG301--TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX W/ANTIRETROVIRAL THERAPY$564
M01 · FY2000 · RR
CEREBROSPINAL FLUID ANALYSIS OF HIV 1 VIRAL BURDEN IN HIV INFECTED SUBJECTS$564
M01 · FY2000 · RR
CSF IN SEVERE AIDS DEMENTIA COMPLEX TREATED WITH A NEW ANTIRETROVIRAL$564
M01 · FY2000 · RR
ACTG 363: EFFECTS OF CIDOFOVIR FOR TREATING PROGRESSIVE MULTIFOCAL PML IN AIDS$564
M01 · FY2000 · RR
CEREBROSPINAL FLUID ANALYSIS OF HIV 1 VIRAL BURDEN IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 363: EFFECTS OF CIDOFOVIR FOR TREATING PROGRESSIVE MULTIFOCAL PML IN AIDS$0
M01 · FY2000 · RR
ACTG 363: EFFECTS OF CIDOFOVIR FOR TREATING PROGRESSIVE MULTIFOCAL PML IN AIDS$0
M01 · FY2000 · RR
CSF IN SEVERE AIDS DEMENTIA COMPLEX TREATED WITH A NEW ANTIRETROVIRAL$0
M01 · FY2000 · RR
CSF IN SEVERE AIDS DEMENTIA COMPLEX TREATED WITH A NEW ANTIRETROVIRAL$0
M01 · FY2000 · RR
ACTG301--TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX W/ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
ACTG301--TRIAL OF MEMANTINE FOR AIDS DEMENTIA COMPLEX W/ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
CEREBROSPINAL FLUID ANALYSIS OF HIV 1 VIRAL BURDEN IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR